

SUPPLEMENTARY MATERIAL

Synthesis of chemically diverse esters of 5-aminolevulinic acid for photodynamic therapy via the multicomponent Passerini reaction.

Gabriel F. Gola^a, Gabriela Di Venosa^b, Daniel A. Sáenz^b, Gustavo H. Calvo^b, Gabriela M. Cabrera^a, Adriana G. Casas^b, Javier A. Ramírez^{a*}.

^a UMYMFOR - Departamento de Química Orgánica y CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Ciudad de Buenos Aires, C1428EGA, Argentina.

^b Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP). CONICET and Hospital de Clínicas José de San Martín, Universidad de Buenos Aires. Córdoba 2351, 1er subsuelo, CP1120AAF, Buenos Aires, Argentina

*Corresponding author: Tel +54 01145763346, Fax +54 01145763385,
e-mail: jar@qo.fcen.uba.ar

Contents:

Synthetic procedures.	S2
Estimated logD for CBz-protected esters of ALA.	S9
PDT curves for compounds 1f and 1g .	S10
NMR and MS spectra of new compounds.	S11

Synthetic procedures.

N-(benzyloxycarbonyl)-5-aminolevulinic acid (2)

5-Aminolevulinic acid (499 mg, 2.98 mmol) was dissolved in 2.5 mL of methanol and cooled in an ice bath. 0.45 mL of benzyloxycarbonyl chloride (Z-Cl) was added, followed by a solution of 0.83 mL of triethylamine in 0.5 mL of methanol, which was added dropwise. After completion of the addition, the reaction mixture was stirred at room temperature for 2 h. The solution was poured into 15 mL of 5% hydrochloric acid. A white precipitated was formed, which was dissolved by adding 40 mL of ethyl acetate. The organic layer was separated, washed with brine (20 mL), water (2 x 20 mL) and finally dried. After evaporation under reduced pressure a crude product was obtained, which was crystallized from ethyl acetate-hexane to yield 67 % of **2** (532 mg).

General procedure for the P-3CR.

To a solution of *N*-(benzyloxycarbonyl)-5-aminolevulinic acid (**2**) in CH₂Cl₂ (0.4 mL / 0.1 mmol of **2**) 1.1 equivalents of formaldehyde (37% aq.) were added, followed by the addition of 1.1 equivalents of the corresponding isocyanide. The mixture was stirred vigorously at room temperature until total disappearance of the acid was observed TLC (usually 24 h). Then, the mixture was concentrated and the residue was purified by silica gel column chromatography, as indicated in each case.

2-(2-ethoxy-2-oxoethylamino)-2-oxoethyl-*N*-(benzyloxycarbonyl)-5-aminolevulinate (3a**)**

Compound **3a** was obtained from 42 mg of **2** (0.16 mmol) and ethyl 2-isocyanoacetate. The crude was purified by column chromatography (98:2 CH₂Cl₂-MeOH) to give **3a** (56 mg; 86%) as a colorless syrup; R_f 0.43 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.60-7.49 (m, 5H, Ar), 7.03 (b.s, 1H), 5.82 (b.s, 1H), 5.31 (s, 2H), 4.84 (s, 2H), 4.41-4.38 (m, 4H), 4.27 (d, J 5.3 Hz, 2H), 3.04 (t, J 6.1 Hz, 2H), 2.93 (t, J 6.1 Hz, 2H), 1.44 (t, J 7.1 Hz, 3H). ¹³C-NMR (CDCl₃) 209.6, 171.0, 169.4, 167.2, 128.5, 128.2, 128.1, 67.1, 62.8, 61.7, 50.5, 40.8, 34.5, 27.6, 14.0. HRMS (ESI) calcd for (M+Na) C₁₉H₂₄N₂NaO₈: 431.1425. Found: 431.1427.

2-(diethoxyphosphorylmethylamino)-2-oxoethyl-*N*-(benzyloxycarbonyl)-5-aminolevulinate (3b**)**

Compound **3b** was obtained from 84 mg of **2** (0.32 mmol) and diethyl (isocyanomethyl)phosphonate. The crude was purified by column chromatography (98:2 CH₂Cl₂-MeOH) to give **3b** (120 mg; 80%) as a colorless syrup; R_f 0.26 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃) 7.38-7.28 (m, 5H, Ar), 6.84 (b.s, 1H, (CO)-NH-CH₂-P), 6.49 (b.s, 1H, O(CO)-NH-CH₂), 5.11

(s, 2H, ArCH₂-O), 4.64 (s, 2H, O-CH₂-(CO)), 4.17 (d, *J* 5.3 Hz, 2H, NH-CH₂-(CO)), 4.08 (p, *J* 7.4 Hz, 4H, PO-CH₂CH₃), 3.73 (dd, *J* 6.1, 12.1 Hz, 2H, NH-CH₂-P), 2.87 (t, *J* 6.1 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.69 (t, *J* 6.1 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 1.27 (t, *J* 7.1 Hz, 6H, PO-CH₂CH₃). ¹³C-NMR (CDCl₃) 205.8 (C=O ketone), 171.1 (C=O)-O), 167.0 (C=O)-NH), 156.7 (O-(C=O)-NH); 136.4, 128.4, 128.1, 128.0 (Ar); 66.9 (Ar-CH₂-O); 62.81, 62.75, 62.74 (PO-CH₂CH₃; O-CH₂-(CO)); 50.5 (NH-CH₂-(CO)); 35.1, 33.8 (NH-CH₂-P); 34.8((CO)-CH₂-CH₂-(CO)-O), 27.7((CO)-CH₂-CH₂-(CO)-O); 16.33, 16.29 (PO-CH₂CH₃). HRMS (ESI) calcd for (M+H) C₂₀H₃₀N₂O₉P: 473.1683. Found: 473.1661.

2-(3,4-dimethoxyphenethylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinic acid (3c)

Compound **3c** was obtained from 40 mg of **2** (0.15 mmol) and 4-(2-isocyanoethyl)-1,2-dimethoxybenzene. The crude was purified by column chromatography (98:2 CH₂Cl₂-MeOH) to give **3c** (59 mg; 81%) as a colorless syrup; R_f 0.30 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.38-7.29 (m, 5H, Ar), 6.78 (d, *J* 7.9 Hz, 1H, Ph(OMe)₂), 6.72 (m, 2H, Ph(OMe)₂), 6.47 (b.s, 1H, (CO)-NH-CH₂CH₂), 5.40 (b.s, 1H, O-(CO)-NH-CH₂), 5.10 (s, 2H, Ar-CH₂-O), 4.58 (s, 2H, O-CH₂-(CO)), 4.08 (d, *J* 5.4 Hz, 2H, NH-CH₂-(CO)), 3.85, 3.83 (2s, 6H, Ar-OCH₃), 3.53 (q, *J* 6.8 Hz, 2H, NH-CH₂-CH₂-Ar), 2.79 (m, 4H, NH-CH₂-CH₂-Ar, (CO)-CH₂-CH₂-(CO)-O), 2.60 (t, *J* 6.1 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O). ¹³C-NMR (CDCl₃): 204.6 (C=O ketone), 171.2 ((C=O)-O), 166.9 ((C=O)-NH), 156.2 (O-(C=O)-NH); 148.9, 147.6, 136.1, 131.3, 128.5, 128.2, 128.1, 120.7, 112.1, 111.3 (Ar), 67.1 (Ar-CH₂-O), 63.0 (O-CH₂-(CO)); 55.89, 55.85 (Ar-OCH₃); 50.3 (NH-CH₂-(CO)), 40.6 (NH-CH₂-CH₂-Ar); 35.0, 34.5 ((CO)-CH₂-CH₂-(CO)-O; NH-CH₂-CH₂-Ar); 27.5 ((CO)-CH₂-CH₂-(CO)-O). HRMS (ESI) calcd for (M+H) C₂₅H₃₁N₂O₈: 487.2075. Found: 487.2095.

2-(*t*-butylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinic acid (3d)

Compound **3d** was obtained from 47 mg of **2** (0.18 mmol) and 2-isocyano-2-methylpropane. The crude was purified by column chromatography (100:1 CH₂Cl₂-MeOH) to give **3d** (61 mg; 91%) as a colorless syrup; R_f 0.43 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.35 (m, 5H), 6.03 (b.s, 1H), 5.41 (b.s, 1H), 5.12 (s, 2H), 4.47 (s, 2H), 4.14 (d, *J* 5.2 Hz, 2H), 2.82 (t, *J* 6.1 Hz, 2H), 2.69 (t, *J* 6.1 Hz, 2H), 1.38 (s, 9H). ¹³C-NMR (CDCl₃): 204.4, 171.3, 166.1, 156.3, 136.3, 128.7, 128.4, 128.2, 110.1, 67.2, 63.5, 51.6, 50.6, 34.6, 28.8. HRMS (ESI) calcd for (M+Na) C₁₉H₂₆N₂O₆Na: 401.1683. Found: 401.1667.

2-(cyclohexylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinic acid (3e)

Compound **3e** was obtained from 29 mg of **2** (0.11 mmol) and isocyanocyclohexane. The crude was purified by column chromatography (98:2 CH₂Cl₂-MeOH) to give **3e** (35 mg; 80%) as a colorless syrup; R_f 0.39 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.30-7.39 (m, 5H, Ar), 6.23 (d, *J* 7.1

Hz, 1H), 5.38 (b.s, 1H), 5.12 (s, 2H), 4.56 (s, 2H), 4.15 (d, *J* 5.3 Hz, 2H), 3.81 (m, 1H), 2.84 (t, *J* 6.0 Hz, 2H), 2.69 (t, *J* 6.2 Hz, 2H), 1.92 (m, 2H), 1.76-1.57 (m, 4H), 1.36 (m, 2H), 1.26-1.12 (m, 2H). ^{13}C -NMR (CDCl_3): 203.9, 171.2, 165.3, 128.5, 128.0, 67.2, 63.1, 50.4, 48.1, 34.6, 32.9, 27.6, 25.5, 24.9. HRMS (ESI) calcd for (M+H) $\text{C}_{21}\text{H}_{29}\text{N}_2\text{O}_6$: 405.2020. Found: 405.2029.

2-((4-fluorophenyl)amino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinate (3f)

Compound **3f** was obtained from 60 mg of **2** (0.23 mmol) and 1-fluoro-4-isocyanobenzene. The crude was purified by column chromatography (70:0.4 and 50:0.4 CH_2Cl_2 -MeOH) to give **3f** (70 mg; 75%) as a colorless syrup; *R*f 0.50 (95:5 CH_2Cl_2 -MeOH); ^1H -NMR (CDCl_3): 8.27 (b.s, 1H), 7.65 (dd, *J* 8.9, 4.8 Hz, 2H), 7.33 (m, 5H), 6.96 (t, *J* 8.5 Hz, 2H), 5.37 (b.s, 1H), 5.08 (s, 2H), 4.72 (s, 2H), 4.13 (d, *J* 5.4 Hz, 2H), 2.90 (t, *J* 6.0 Hz, 2H), 2.71 (t, *J* 6.0 Hz, 2H). ^{13}C -NMR (CDCl_3): 206.1, 171.5, 165.4, 160.6, 158.7, 156.4, 136.1, 133.4, 133.3, 128.7, 128.5, 128.2, 122.1, 122.0, 115.8, 115.6, 67.4, 63.1, 50.4, 35.0, 27.9. HRMS (ESI) calcd for (M+H) $\text{C}_{21}\text{H}_{21}\text{FN}_2\text{O}_6\text{Na}$: 439.1276. Found: 439.1281.

2-(4-tolylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinate (3g)

Compound **3g** was obtained from 63 mg of **2** (0.24 mmol) and 1-isocyno-4-methylbenzene. The crude was purified by column chromatography (100:1 CH_2Cl_2 -MeOH) to give **3g** (79 mg; 81%) as a colorless syrup; *R*f 0.45 (95:5 CH_2Cl_2 -MeOH); ^1H -NMR (CDCl_3): 8.16 (b.s, 1H, (CO)-NH-Ar), 7.54 (d, *J* 8.0 Hz, 2H, Ar(*m*-H)-CH₃), 7.33 (m, 5H, Ar), 7.08 (d, *J* 8.0 Hz, 2H, Ar(*o*-H)-CH₃), 5.41 (b.s, 1H, (CO)-NH-CH₂), 5.08 (s, 2H, Ar-CH₂-O), 4.70 (s, 2H, O-CH₂-(CO)), 4.12 (d, *J* 5.3 Hz, 2H, NH-CH₂-(CO)), 2.86 (t, *J* 6.0 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.71 (t, *J* 6.0 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.27 (s, 2H, Ar-CH₃). ^{13}C -NMR (CDCl_3): 205.6 (C=O ketone), 171.5 ((C=O)-O), 165.2 ((C=O)-NH), 156.4 (O-(C=O)-NH); 136.2, 134.7, 134.5, 129.6, 128.7, 128.4, 128.2, 120.3 (Ar); 67.3 (Ar-CH₂-O), 63.2 (O-CH₂-(CO)), 50.5 (NH-CH₂-(CO)), 34.9 ((CO)-CH₂-CH₂-(CO)-O), 27.9 ((CO)-CH₂-CH₂-(CO)-O), 21.0 (Ar-CH₃). HRMS (ESI) calcd for (M+H) $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_6$: 413.1707. Found: 413.17071.

2-((2-(trifluoromethyl)phenyl)amino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinate (3h)

Compound **3h** was obtained from 60 mg of **2** (0.23 mmol) and 1-isocyno-2-(trifluoromethyl)benzene. The crude was purified by column chromatography (100:1 CH_2Cl_2 -MeOH) to give **3h** (89 mg; 84%) as a colorless syrup; *R*f 0.50 (95:5 CH_2Cl_2 -MeOH); ^1H -NMR (CDCl_3): 8.36 (b.s, 1H), 8.24 (d, *J* 8.3 Hz, 1H), 7.63 (d, *J* 7.8 Hz, 1H), 7.57 (t, *J* 7.8 Hz, 1H), 7.34 (m, 5H), 7.27 (t, *J* 7.8 Hz, 1H), 5.47 (b.s, 1H), 5.10 (s, 2H), 4.74 (s, 2H), 4.14 (d, *J* 5.1 Hz, 2H), 2.80 (m, 4H). ^{13}C -NMR (CDCl_3): 203.7, 170.9, 165.4, 156.3, 136.3, 134.3, 133.2, 128.6, 128.3, 128.2,

126.40, 126.35, 126.31, 126.27, 125.22, 125.15, 124.2, 123.1, 67.2, 63.3, 50.6, 34.3, 27.5. HRMS (ESI) calcd for (M+H) C₂₂H₂₂F₃N₂O₆: 467.1425. Found: 467.1420.

2-((4-bromo-2-methylphenyl)amino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinate (3i)

Compound **3i** was obtained from 61 mg of **2** (0.23 mmol) and 4-bromo-1-isocyano-2-methylbenzene. The crude was purified by column chromatography (70:0.4 and 50 : 0.4 CH₂Cl₂-MeOH) to give **3i** (94 mg; 84%) as a colorless syrup; Rf 0.45 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.92 (b.s, 1 H, (CO)-NH-Ar), 7.61 (d, J 8.4 Hz, 1H, Ar), 7.40-7.28 (m, 7H, Ar), 5.37 (b.s, 1H, (CO)-NH-CH₂), 5.07 (s, 2H, Ar-CH₂-O), 4.73 (s, 2H, O-CH₂-(CO)), 4.10 (d, J 5.2 Hz, 2H, O-CH₂-(CO)), 2.85 (t, J 5.9 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.73 (t, J 5.9 Hz, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.23 (s, 3H, Ar-CH₃). ¹³C-NMR (CDCl₃): 204.8 (C=O ketone), 171.4 ((C=O)-O), 165.4 ((C=O)-NH), 156.3 (O-(C=O)-NH); 136.2, 133.8, 133.4, 132.6, 129.8, 128.7, 128.4, 128.2, 125.3, 119.0 (Ar); 67.3 (Ar-CH₂-O), 63.5 (O-CH₂-(CO)), 50.5 (NH-CH₂-(CO)), 34.6 ((CO)-CH₂-CH₂-(CO)-O), 27.8 ((CO)-CH₂-CH₂-(CO)-O), 17.5 (Ar-CH₃). HRMS (ESI) calcd for (M+Na) C₂₂H₂₃BrN₂O₆Na: 513.0632. Found: 513.0647.

2-oxo-2-(pentadecylamino)ethyl-N-(benzyloxycarbonyl)-5-aminolevulinate (3j)

Compound **3j** was obtained from 39 mg of **2** (0.15 mmol) and 1-isocyanopentadecane. The crude was purified by column chromatography (98:2 CH₂Cl₂-MeOH) to give **3j** (50 mg; 63%) as a colorless syrup; Rf 0.43 (95:5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 7.40-7.29 (m, 5H, Ar), 6.38 (b.s, 1H), 5.40 (b.s, 1H), 5.12 (s, 2H), 4.58 (s, 2H), 4.14 (d, J 4.6 Hz, 2H), 3.29 (q, J 6.8 Hz, 2H), 2.83 (t, J 5.6 Hz, 2H), 2.69 (t, J 5.6 Hz, 2H), 1.73-1.20 (m, 26H), 0.88 (t, J 6.8 Hz, 3H). ¹³C-NMR (CDCl₃): 204.5, 171.2, 166.8, 128.3, 128.1, 67.2, 63.1, 50.4, 39.3, 34.6, 31.9, 29.70, 29.66, 29.61, 29.57, 29.42, 29.37, 29.29, 27.6, 26.9, 22.7, 14.1. HRMS (ESI) calcd for (M+H) C₃₀H₄₉N₂O₆: 533.3585. Found: 533.3585.

General procedure for the deprotection of the Passerini products.

A stirred suspension of the corresponding intermediates **3a-j**, dissolved in 10:1 MeOH-CHCl₃ (3 mL / 0.1 mmol of substrate) and palladium black (0.1 equivalents) was hydrogenated at atmospheric pressure at room temperature. After completion of the reaction (usually for 4 h, controlled by TLC), the mixture was filtered through celite and the solvent was removed *in vacuo*. The crude product was purified by recrystallization or silica gel column chromatography, as indicated in each case.

2-(2-ethoxy-2-oxoethylamino)-2-oxoethyl-5-aminolevulinate (1a)

Compound **1a** was obtained from 40 mg (0.098 mmol) of **3a**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 24 mg of **1a** (90%) as a white solid. Rf 0.08 (93:7 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 4.64 (s, 2H), 4.22 (q, J 7.1 Hz, 2H), 4.03 (d, J 6.5 Hz, 4H), 2.92 (b. dt, J 6.2, 2.0 Hz, 2H), 2.84 (b. dt, J 6.2, 2.0 Hz, 2H), 1.30 (t, J 7.1 Hz, 3H). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.4, 171.5, 169.7, 168.3, 62.4, 61.4, 47.0, 40.6, 34.2, 27.2, 13.7. HRMS (ESI) calcd for (M+Na) C₁₁H₁₈N₂NaO₆: 297.1057. Found: 297.1048.

2-(diethoxyphosphorylmethylamino)-2-oxoethyl-5-aminolevulinate (1b)

Compound **1b** was obtained from 43 mg (0.092 mmol) of **3b**. The crude product was purified by column chromatography (98:2 and 95:5 CH₂Cl₂-MeOH) to yield 28 mg of **1b** (89%) as a colorless syrup. Rf 0.32 (8:2 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 8.23 (bs, 2H), 4.69 (s, 2H), 4.28 (bs, 2H), 4.15 (m, 4H), 3.85 (bs, 2H), 3.47 (bs, 1H), 3.03 (bs, 2H), 2.85 (bs, 2H), 1.31 (t, J 7.1 Hz, 6H). ¹³C-NMR (CDCl₃): 203.5, 172.6, 168.5, 63.8, 63.7, 63.2, 63.0, 62.95, 62.9, 48.2, 35.3, 35.0, 34.0, 33.8, 32.5, 29.3, 27.8, 16.5. HRMS (ESI) calcd for (M+Na) C₁₂H₂₃N₂NaO₇P: 361.1135. Found: 361.1154.

2-(3,4-dimethoxyphenethylamino)-2-oxoethyl-5-aminolevulinate (1c)

Compound **1c** was obtained from 49 mg (0.101 mmol) of **3c**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 22 mg of **1c** (63%) as white solid. Rf 0.09 (93:7 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 6.84 (d, J 8.7 Hz, 1H, Ar), 6.77 (m, 2H, Ar), 4.54 (s, 2H, O-CH₂-(CO)), 4.02 (s, 2H, NH₂-CH₂-(CO)), 3.88 (s, 3H, Ar-OCH₃), 3.86 (s, 3H, Ar-OCH₃), 3.48 (t, J 7.4 Hz, 2H, NH-CH₂-Ar), 2.87 (t, J 6.3 Hz, 2H, (CO)-CH₂-CH₂-(CO)O), 2.80 (t, J 7.4 Hz, 2H, NH-CH₂-CH₂-Ar), 2.77 (t, J 6.3 Hz, 2H, (CO)-CH₂-CH₂-(CO)O). ¹³C-RMN (CDCl₃, CD₃OD 9:1): 201.2 (C=O ketone), 171.4 ((C=O)-O), 167.4 ((C=O)-NH); 148.6, 147.3, 131.2, 120.5, 111.9, 111.2 (Ar); 62.6 (O-CH₂-(CO)); 55.6, 55.6 (Ar-OCH₃); 46.9 (NH₂-CH₂-(CO)), 40.5 (NH-CH₂-CH₂-Ar), 34.7 ((CO)-CH₂-CH₂-(CO)-O), 34.1 (NH-CH₂-CH₂-Ar), 27.1 ((CO)-CH₂-CH₂-(CO)-O). HRMS (ESI) calcd for (M+Na) C₁₇H₂₄N₂NaO₆: 375.1527. Found: 375.1510.

2-(t-butylamino)-2-oxoethyl-5-aminolevulinate (1d)

Compound **1d** was obtained from 41 mg (0.108 mmol) of **3d**. The crude product was purified by column chromatography (95:5 and 9:1 CH₂Cl₂-MeOH) to yield 24 mg of **1d** (89%) as a colorless syrup. Rf 0.26 (8:2 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 8.14 (b.s, 2H), 4.64 (b.s, 2H), 4.40 (b.s, 2H), 3.09 (b.s, 2H), 2.85(b.s, 2H), 1.43 (m, 12H). ¹³C-NMR (CDCl₃): 203.2, 172.5, 171.3, 167.1, 166.1, 63.7, 63.5, 51.8, 51.6, 50.7, 48.2, 35.0, 32.3, 29.3, 28.84, 28.79, 28.7, 27.6. HRMS (ESI) calcd for (M+Na) C₁₁H₂₀N₂NaO₄: 267.1315. Found: 267.1311.

2-(cyclohexylamino)-2-oxoethyl-5-aminolevulinic acid (1e)

Compound **1e** was obtained from 27 mg (0.067 mmol) of **3e**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 16 mg of **1e** (90%), as a white solid. Rf 0.39 (9 : 5 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 8.25 (b.s, 1H), 4.55 (s, 2H), 4.18 (s, 2H), 3.71 (m, 1H), 3.00-2.73 (m, 6H), 1.87 (m, 2H), 1.74 (m, 2H), 1.63 (m, 1H), 1.40-1.11 (m, 5H). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 202.5, 172.2, 166.7, 63.2, 48.6, 48.5, 47.7, 34.7, 32.71, 32.68, 27.5, 25.4, 25.0. HRMS (ESI) calcd for (M+Na) C₁₃H₂₂N₂NaO₄: 293.1472. Found: 293.1466.

2-((4-fluorophenyl)amino)-2-oxoethyl-5-aminolevulinic acid (1f)

Compound **1f** was obtained from 47 mg (0.113 mmol) of **3f**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 23 mg of **1f** (73%) as a white solid. Rf 0.20 (85:15 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 7.56 (m, 2H), 7.03 (m, 2H), 4.72 (s, 2H), 4.01 (s, 2H), 2.89 (m, 4H). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.0, 171.7, 165.9, 160.2, 158.2, 133.2, 133.1, 121.8, 121.7, 115.0, 114.8, 62.3, 46.7, 33.9, 27.0. HRMS (ESI) calcd for (M+H) C₁₃H₁₆N₂FO₄: 283.1089. Found: 283.1098.

2-(4-tolylamino)-2-oxoethyl-5-aminolevulinic acid (1g)

Compound **1g** was obtained from 55 mg (0.133 mmol) of **3g**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 22 mg of **1g** (61%) as a white solid. Rf 0.20 (85:15 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 7.44 (d, J 8.3 Hz, 2H, Ar), 7.13 (d, J 8.3 Hz, 2H, Ar), 4.71 (s, 2H, O-CH₂-(CO)), 4.01 (s, 2H, NH₂-CH₂-(CO)), 2.88 (m, 4H, (CO)-CH₂-CH₂-(CO)-O, (CO)-CH₂-CH₂-(CO)-O), 2.32 (s, 2H, Ar-CH₃). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.2 (C=O ketone), 171.7 ((C=O)-O), 165.9 ((C=O)-NH); 134.4, 134.1, 129.0, 120.2 (Ar); 62.5 (O-CH₂-(CO)), 46.8 (NH₂-CH₂-(CO)), 34.0 ((CO)-CH₂-CH₂-(CO)-O), 27.2 ((CO)-CH₂-CH₂-(CO)-O), 20.2 (Ar-CH₃). HRMS (ESI) calcd for (M+H) C₁₄H₁₉N₂O₄: 279.1339. Found: 279.1338.

2-((2-(trifluoromethyl)phenyl)amino)-2-oxoethyl-5-aminolevulinic acid (1h)

Compound **1h** was obtained from 48 mg (0.104 mmol) of **3h**. The crude product was purified by recrystallization from CH₂Cl₂ to yield 29 mg of **1h** (85%) as a white solid. Rf 0.30 (85:15 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 8.01 (d, J 8.2 Hz, 1H), 7.67 (d, J 7.9 Hz, 1H), 7.61 (t, J 7.9 Hz, 1H), 7.35 (t, J 7.7 Hz, 1H), 4.76 (s, 2H), 4.02 (s, 2H), 2.91 (m, 2H), 2.86 (m, 2H). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.0, 171.2, 166.1, 133.8, 132.9, 126.31, 126.26, 125.8, 125.7, 63.0, 47.1, 34.3, 27.2. HRMS (ESI) calcd for (M+Na) C₁₄H₁₅F₃N₂NaO₄: 355.0876. Found: 355.0881.

2-oxo-2-(pentadecylamino)ethyl-5-aminolevulinate (1j)

Compound **1j** was obtained from 35 mg (0.066 mmol) of **3j**. The crude product was purified by column chromatography (95:5 and 9:1 CH₂Cl₂-MeOH) to yield 14 mg of **1j** (33%), a pale yellow solid. Rf 0.14 (9:1 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃): 4.55 (s, 2H), 4.03 (s, 2H), 3.24 (t, J 7.3 Hz, 2H), 2.89 (t, J 6.3 Hz, 2H), 2.80 (t, J 6.3 Hz, 2H), 1.53 (b.s, 2H), 1.34-1.22 (m, 24H), 0.88 (t, J 6.8 Hz, 3H). ¹³C-NMR (CDCl₃): 201.5, 171.6, 171.4, 167.4, 62.8, 47.1, 39.3, 34.4, 31.8, 29.58, 29.56, 29.54, 29.52, 29.50, 29.48, 29.45, 29.25, 29.22, 29.20, 27.4, 26.83, 26.79, 22.6, 13.9. HRMS (ESI) calcd for (M+H) C₂₂H₄₃N₂O₄: 399.3217. Found: 399.3197.

2-((4-bromo-2-methylphenyl)amino)-2-oxoethyl-5-aminolevulinate (1i)

Unexpectedly, when the general procedure deprotection procedure was applied to 67 mg (0.136 mmol) of **3i**, the target compound **1i** was not obtained. After purification of the resulting product by recrystallization from CH₂Cl₂, 40 mg of a white solid was obtained, which was identified as **2-((2-methylphenyl)amino)-2-oxoethyl-5-aminolevulinate (1k)**. Rf 0.24 (85:15 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 7.42 (dd, 1H, J 7.8; 1.4 Hz, Ar), 7.26-7.13 (m, 3H, Ar), 4.78 (s, 2H, O-CH₂-(CO)), 4.02 (s, 2H, NH₂-CH₂-(CO)), 2.91 (m, 2H, (CO)-CH₂-CH₂-(CO)-O), 2.87 (m, 2H, (CO)-CH₂-CH₂-(CO)-O)), 2.27 (s, 3H, Ar-CH₃). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.0 (C=O ketone), 171.7 ((C=O)-O), 166.5 ((C=O)-NH); 134.1, 132.3, 130.3, 126.3, 126.1, 125.0 (Ar); 62.6 (O-CH₂-(CO)), 46.9 (NH₂-CH₂-(CO)), 34.2 ((CO)-CH₂-CH₂-(CO)-O), 27.2 ((CO)-CH₂-CH₂-(CO)-O), 17.1 (Ar-CH₃). HRMS (ESI) calcd for (M+H) C₁₄H₁₉N₂O₄: 279.1339. Found: 279.1336.

Compound **1i** was obtained by an alternative procedure: Compound **3i** (20 mg, 0.041 mmol) was dissolved in trifluoroacetic acid and 50 equivalents of thioanisole were slowly added. The mixture was stirred vigorously for 3 hours at room temperature and subsequently the solvents were removed *in vacuo*. CH₂Cl₂ was added and the mixture was evaporated *in vacuo* (3 × 1 mL) to remove any residual TFA. The crude was washed with cyclohexane (2 × 1 mL) and dried *in vacuo* (the flask was heated to 50 °C in a airbath to facilitate evaporation of any residual thioanisole). The crude product was purified by recrystallization from CH₂Cl₂ to yield 15 mg of **1i** (98%) as a white solid. Rf 0.10 (9:1 CH₂Cl₂-MeOH); ¹H-NMR (CDCl₃, CD₃OD 9:1): 7.41 (d, 1H, J 8.6 Hz, Ar), 7.37 (d, 1H, J 1.9 Hz, Ar), 7.32 (dd, 1H, J 8.6; 2.2 Hz, Ar), 4.73 (s, 2H, O-CH₂-(CO)), 3.96 (s, 2H, NH₂-CH₂-(CO)), 2.89-2.80 (m, 4H, (CO)-CH₂-CH₂-(CO)-O, (CO)-CH₂-CH₂-(CO)-O), 2.24 (s, 3H, Ar-CH₃). ¹³C-NMR (CDCl₃, CD₃OD 9:1): 201.5 (C=O ketone), 171.7 ((C=O)-O), 166.3 ((C=O)-NH); 134.0, 133.6, 133.3, 129.4, 126.2, 119.3 (Ar); 62.9 (O-CH₂-(CO)), 46.9 (NH₂-CH₂-(CO)); 34.2, 27.4 ((CO)-CH₂-CH₂-(CO)-O, (CO)-CH₂-CH₂-(CO)-O); 17.2 (Ar-CH₃). HRMS (ESI) calcd for (M+H) C₁₄H₁₈N₂BrO₄: 357.0450 Found: 357.0447.

Table S1. Structures of the CBz-protected esters of ALA with their estimated logD.






Figure S1. Cell survival after photodynamic treatment for compounds **1f** and **1g**. LM2 cells were incubated with different concentrations of the compounds during 3 h. Afterwards, PDT was performed, and cell viability was evaluated by the MTT assay, as percentage of control non-irradiated cells.


¹H-NMR (500 MHz) of compound 2-(2-ethoxy-2-oxoethylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinic acid (3a)



¹³C-NMR (50,3 MHz) of compound **3a**





ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3a** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	rb	N-Rule e ⁻ Conf
204.1005	C ₁₂ H ₁₄ NO ₂	204.1019	6.9	6.5	ok even id Cy
252.1207	C ₁₃ H ₁₈ NO ₄	252.1230	9.3	5.5	ok even
301.1003	C ₁₂ H ₁₇ N ₂ O ₇	301.1030	8.9	5.5	ok even [M+H-BnOH] ⁺
365.1671	C ₁₈ H ₂₅ N ₂ O ₆	365.1707	9.8	7.5	ok even [M+H-CO ₂] ⁺
409.1574	C ₁₉ H ₂₅ N ₂ O ₈	409.1605	7.7	8.5	ok even [M+H] ⁺


¹H-NMR (500 MHz) of compound 2-(diethoxyphosphorylmethylamino)-2-oxoethyl-*N*-(benzyloxy carbonyl)-5-aminolevulinic (3b)




¹³C-NMR (125.7 MHz) of compound **3b**




HSQC-DEPT (500 MHz) of compound 3b



HMBC (500 MHz) of compound 3b




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3b** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	rdb	N-Rule e ⁻ Conf
91.0538	C ₇ H ₇	91.0542	4.8	4.5	ok even trop ⁺
204.1012	C ₁₂ H ₁₄ N ₀ 2	204.1019	3.4	6.5	ok even id anteriores
208.0715	C ₇ H ₁₅ N ₀ 4P	208.0733	8.9	1.5	ok even ruptura CO-O→-H ₂ O
226.0826	C ₇ H ₁₇ N ₀ 5P	226.0839	5.6	0.5	ok even ruptura CO-O→
319.0671	C ₁₁ H ₁₆ N ₂ O ₇ P	319.0690	5.9	5.5	ok even [M+H- EtOH-BnOH] ⁺
365.1089	C ₁₃ H ₂₂ N ₂ O ₈ P	365.1108	5.3	4.5	ok even [M+H-BnOH] ⁺
383.1346	C ₁₇ H ₂₄ N ₂ O ₆ P	383.1366	5.2	7.5	ok even [M+H- CO ₂ - EtOH] ⁺
429.1773	C ₁₉ H ₃₀ N ₂ O ₇ P	429.1785	2.7	6.5	ok even [M+H- CO ₂] ⁺


¹H-NMR (500 MHz) of compound 2-(3,4-dimethoxyphenethylamino)-2-oxoethyl-N-(benzyloxycarbonyl)-5-aminolevulinic acid (3c)




¹³C-NMR (125.7 MHz) of compound **3c**




—204.618
—171.210
—166.922
—156.167
—148.878
—147.561
—136.097
—131.323
—128.523
—128.236
—128.069
—120.714
—112.122
—111.314
—67.115
—63.009
—55.893
—55.853
—53.404
—50.334
—40.606
—34.989
—34.451
—27.538




HSQC-DEPT (500 MHz) of compound 3c




¹H MBC (500 MHz) of compound 3c




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound 3c (collision Energy 10 eV)




¹H-NMR (500 MHz) of compound 2-(*t*-butylamino)-2-oxoethyl-*N*-(benzyl oxy carbonyl)-5-aminolevulinic (3d)







ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3d** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	rdb	N-Rule e ⁻ Conf
91.0539	C ₇ H ₇	91.0542	3.9	4.5	ok even trop ⁺
166.0861	C ₉ H ₁₂ N O ₂	166.0863	0.9	4.5	ok even ruptura CO
204.1008	C ₁₂ H ₁₄ N O ₂	204.1019	5.2	6.5	ok even id anteriores
215.0652	C ₈ H ₁₁ N ₂ O ₅	215.0662	4.9	4.5	ok even [M+H-BnOH-propeno] ⁺
279.1329	C ₁₄ H ₁₉ N ₂ O ₄	279.1339	3.6	6.5	ok even [M+H-CO ₂ -propeno] ⁺
335.1948	C ₁₈ H ₂₇ N ₂ O ₄	335.1965	5.1	6.5	ok even [M+H-CO ₂] ⁺


¹H-NMR (500 MHz) of compound 2-(cyclohexylamino)-2-oxoethyl-*N*-(benzyloxycarbonyl)-5-aminolevulinic acid (3e)




¹³C-NMR (50.3 MHz) of compound **3e**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3e** (collision Energy 10 eV)




¹H-NMR (500 MHz) of compound 2-((4-fluorophenyl)amino)-2-oxoethyl-*N*-(benzylloxycarbonyl)-5-aminolevulinic acid (3f)




¹³C-NMR (125.7 MHz) of compound **3f**




ESI MS/MS spectrum of m/z ([M+H] $^+$ cation of compound **3f** (collision Energy 10 eV)




¹H-NMR (500 MHz) for compound 2-(4-tolylamino)-2-oxoethyl-*N*-(benzyloxycarbonyl)-5-aminoevulinate (3g)




¹³C-NMR (125.7 MHz) of compound **3g**




COSY (500 MHz) of compound 3g



HMQC (500 MHz) of compound 3g




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3g** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	rdb	N-Rule e ⁻ Conf
91.05364	C 7 H 7	91.05423	6.4	4.5	ok even
114.05536	C 5 H 8 N O 2	114.05495	-3.5	2.5	ok even
154.04929	C 7 H 8 N O 3	154.04987	3.8	4.5	ok even X
166.08692	C 9 H 12 N O 2	166.08626	-4.0	4.5	ok even α -O Cterm
178.08637	C 10 H 12 N O 2	178.08626	-0.6	5.5	ok even
198.12802	C 14 H 16 N	198.12773	-1.5	7.5	ok even
204.10108	C 12 H 14 N O 2	204.10191	4.0	6.5	ok even 369-165
256.13372	C 16 H 18 N O 2	256.13321	-2.0	8.5	ok even 369-113
369.18078	C 21 H 25 N 2 O 4	369.18088	0.3	10.5	ok even -CO2


¹H-NMR (500 MHz) of compound 2-((2-(trifluoromethyl)phenyl)-2-oxoethyl-N-(benzoyloxycarbonyl)-5-aminolevulininate (**3h**)




¹³C-NMR (125.7 MHz) of compound **3h**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3h** (collision Energy 10 eV)




¹H-NMR (500 MHz) of compound 2-((4-bromo-2-methylphenyl)amino)-2-oxoethyl-*N*-(benzyloxycarbonyl)-5-aminolevulinic (3i)




¹³C-NMR (125,7 MHz) of compound **3i**




COSY (500 MHz) of compound **3i**




HSQC-DEPT (500 MHz) of compound 3i



HMBC (500 MHz) of compound 3i




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3i** (collision Energy 10 eV)




:as. m/z	Formula	m/z	err [ppm]	rdb	N-Rule e ⁻ Conf
05352	C 7 H 7	91.05423	7.7	4.5	ok even
4.05558	C 5 H 8 N O 2	114.05495	-5.5	2.5	ok even
4.04991	C 7 H 8 N O 3	154.04987	-0.3	4.5	ok even
5.09290	C 12 H 12 N O	186.09134	-8.4	7.5	ok even 204-H2O
4.10329	C 12 H 14 N O 2	204.10191	-6.8	6.5	ok even id ant
5.99826	C 10 H 11 Br N O 2	255.99677	-5.8	5.5	ok even
5.03878	C 14 H 15 Br N	276.03824	-2.0	7.5	ok even
4.04433	C 16 H 17 Br N O 2	334.04372	-1.8	8.5	ok even 447-113
7.09401	C 21 H 24 Br N 2 O 4	447.09140	-5.8	10.5	ok even -CO2


¹H-NMR (500 MHz) of compound 2-oxo-2-(pentadecylamino)ethyl-N-(benzyl oxy carbonyl)-5-aminolevulinic acid (3j)




¹³C-NMR (50,3 MHz) of compound **3j**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **3j** (collision Energy 10 eV)




¹H-NMR (500 MHz) of compound 2-(2-ethoxy-2-oxoethylamino)-2-oxoethyl-5-aminolevulinic (1a)



¹³C-NMR (125,7 MHz) for compound **1a**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1a** (collision Energy 10 eV)





Meas. m/z	Formula	m/z	err [ppm]	ldb	N-Rule e ⁻ Conf
86.0601	C ₄ H ₈ NO	86.0600	-0.5	1.5	ok even ruptura αCOO
88.0392	C ₃ H ₆ NO ₂	88.0393	0.9	1.5	ok even ruptura αCON
114.0558	C ₅ H ₈ NO ₂	114.0550	-7.5	2.5	ok even ruptura COO←
116.0348	C ₄ H ₆ NO ₃	116.0342	-5.4	2.5	ok even ruptura CON→
154.0496	C ₇ H ₈ NO ₃	154.0499	2.0	4.5	ok even X
162.0766	C ₆ H ₁₂ NO ₄	162.0761	-2.9	1.5	ok even ruptura COO→
275.1225	C ₁₁ H ₁₉ N ₂ O ₆	275.1238	4.5	3.5	ok even [M+H] ⁺

¹H-NMR (500 MHz) for compound 2-(diethoxyphosphorylmethylamino)-2-oxoethyl-5-aminolevulinic (1b)




¹³C-NMR (125,7 MHz) for compound **1b**






HSQC-DEPT (500 MHz) for compound **1b**

HMBC (500 MHz) for compound 1b



ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1b** (collision Energy 10 eV)




Meas. m/z Formula m/z err [ppm] rdb N-Rule e⁻ Conf


114.0574

139.0540	C ₁₁ H ₇	139.0542	1.4	8.5	ok	even
	C ₇ H ₁₀ N P	139.0545	3.6	4.0	ok	odd
142.0883	C ₇ H ₁₂ N O ₂	142.0863	-14.5	2.5	ok	even
154.0518	C ₇ H ₈ N O ₃	154.0499	-12.8	4.5	ok	even
168.0811	C ₈ H ₁₃ N ₂ P	168.0811	0.0	4.0	ok	odd
	C ₁₂ H ₁₀ N	168.0808	-1.8	8.5	ok	even
180.0445	C ₅ H ₁₁ N O ₄ P	180.0420	-13.9	1.5	ok	even
198.0551	C ₅ H ₁₃ N O ₅ P	198.0526	-12.7	0.5	ok	even
208.0756	C ₇ H ₁₅ N O ₄ P	208.0733	-10.8	1.5	ok	even
226.0866	C ₇ H ₁₇ N O ₅ P	226.0839	-12.0	0.5	ok	even
293.0917	C ₁₀ H ₁₈ N ₂ O ₆ P	293.0897	-6.9	3.5	ok	even
339.1338	C ₁₂ H ₂₄ N ₂ O ₇ P	339.1316	-6.4	2.5	ok	even
						[M+H] ⁺


¹H-NMR (500 MHz) for compound 2-(3,4-dimethoxyphenylamino)-2-oxoethyl-5-aminoevulinate (**1c**)




¹³C-NMR (125.7 MHz) for compound **1c**




HSQC-DEPT (500 MHz) for compound **1c**






HMBc (500 MHz) for compound **1c**


ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1c** (collision Energy 15 eV)




Meas. m/z	Formula	m/z	err [ppm]	ldb	N-Rule e ⁻ Conf
114.0563	C ₅ H ₈ NO ₂	114.0550	-12.1	2.5	ok even ruptura CO-O-<
154.0507	C ₇ H ₈ NO ₃	154.0499	-5.4	4.5	ok even X
165.0926	C ₁₀ H ₁₃ O ₂	165.0910	-9.7	4.5	ok even ruptura α NH →
240.1241	C ₁₂ H ₁₈ NO ₄	240.1230	-4.4	4.5	ok even ruptura CO-O→
353.1695	C ₁₇ H ₂₅ N ₂ O ₆	353.1707	3.4	6.5	ok even [M+H] ⁺



¹³C-NMR (125.7 MHz) for compound **1d**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1d** (collision Energy 15 eV)




Meas. m/z	Formula	m/z	err [ppm]rdb	N-Rule e ⁻ Conf		
114.0565	C 5 H 8 N O 2	114.0550-14.0	2.5	ok	even	ruptura CO-O<
132.1026	C 6 H 14 N O 2	132.1019-5.5	0.5	ok	even	ruptura COO→
154.0505	C 7 H 8 N O 3	154.0499-4.1	4.5	ok	even	X
189.0876	C 7 H 13 N 2 O 4	189.0870-3.4	2.5	ok	even	[M+H-C ₄ H ₈] ⁺


¹H-NMR (500 MHz) for compound 2-(cyclohexylamino)-2-oxoethyl-5-aminoethyl-5-aminolevulinic acid (1e)





¹³C-NMR (125,7 MHz) for compound **1e**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1e** (collision Energy 15 eV)




¹H-NMR (500 MHz) for compound 2-((4-fluorophenyl)amino)-2-oxoethyl-5-aminoevulinate (1f)



¹³C-NMR (125,7 MHz) for compound **1f**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1f** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	e^- Conf	N-Rule	mSigma
86.06002	C 4 H 8 N O	86.06004	0.3	even	ok	5.2
114.05566	C 5 H 8 N O 2	114.05495	-6.2	even	ok	0.7
154.04981	C 7 H 8 N O 3	154.04987	0.4	even	ok	2.4
170.06184	C 8 H 9 F N O 2	170.06118	-3.9	even	ok	22.5
265.09900	C 13 H 14 F N 2 O 3	265.09830	-2.7	even	ok	10.9


¹H-NMR (500 MHz) for compound 2-(4-tolylamino)-2-oxoethyl-5-aminovalinamate (**1g**)




¹³C-NMR (125,7 MHz) for compound **1g**




COSY (500 MHz) for compound **1g**



HSQC-DEPT (500 MHz) for compound **1g**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1g** (collision Energy 10 eV)




eas. m/z	Formula	m/z	err [ppm]	e ⁻ Conf	N-Rule	mSigma
8.08032	C 7 H 10 N	108.08078	4.2	even ok	5.0	
4.05464	C 5 H 8 N O 2	114.05495	2.7	even ok	1.7	
0.08047	C 8 H 10 N	120.08078	2.6	even ok	11.3	
8.07492	C 9 H 10 N O	148.07569	5.2	even ok	11.4	166-H2O
4.04923	C 7 H 8 N O 3	154.04987	4.2	even ok	3.3	
6.08630	C 9 H 12 N O 2	166.08626	-0.3	even ok	3.4	
1.12249	C 14 H 17 N 2 O 3	261.12337	3.3	even ok	21.4	
279.13364	C 14 H 19 N 2 O 4	279.13393	1.0	even ok	5.6	


¹H-NMR (500 MHz) for compound 2-((2-(trifluoromethyl)phenyl)amino)-2-oxoethyl-5-aminolevulinic acid (1h)



¹³C-NMR (125,7 MHz) for compound **1h**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1h** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]	rdb	e ⁻ Conf	N-Rule
200.0513	C 9 H 8 F 2 N O 2	200.0518	2.3	5.5	even	ok
220.0576	C 9 H 9 F 3 N O 2	220.0580	2.0	4.5	even	ok
255.0761	C 11 H 12 F N 2 O 4	255.0776	5.7	6.5	even	ok
	C 12 H 10 F 3 N 2 O	255.0740	-8.3	7.5	even	ok
	C 14 H 11 N 2 O 3	255.0764	1.3	10.5	even	ok
	C 12 H 12 F 3 N 2 O 2	273.0845	-7.7	6.5	even	ok
273.0866	C 14 H 13 N 2 O 4	273.0870	1.3	9.5	even	ok
	C 14 H 14 F 3 N 2 O 3	315.0951	-1.7	7.5	even	ok
315.0956	C 14 H 16 F 3 N 2 O 4	333.1057	-5.8	6.5	even	ok
333.1076						-3FH?


¹H-NMR (500 MHz) for compound 2-((4-bromo-2-methylphenyl)amino)-2-oxoethyl-5-aminolevulinate (**1i**)




¹³C-NMR (125,7 MHz) for compound **1i**




COSY (500 MHz) for compound **1i**




HMBC (500 MHz) for compound 1i





HSQC-DEPT (500 MHz) for compound 1i




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1i** (collision Energy 10 eV)




¹H-NMR (500 MHz) for compound 2-oxo-2-(pentadecylamino)ethyl-5-aminolevulinic (1j)



¹³C-NMR (125.7 MHz) for compound **1j**




ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1j** (collision Energy 10 eV)




Meas. m/z	Formula	m/z	err [ppm]rdb	N-Rule	e ⁻ Conf	Asignac.
114.0554	C 5 H 8 N O 2	114.0550	-4.2	2.5	ok	even ruptura CO-O-<
154.0497	C 7 H 8 N O 3	154.0499	0.9	4.5	ok	even X
228.2675	C 15 H 34 N	228.2686	4.8	-0.5	ok	even RNH ₃ ⁺
286.2730	C 17 H 36 N O 2	286.2741	3.5	0.5	ok	even ruptura CO-O->
399.3200	C 22 H 43 N 2 O 4	399.3217	4.2	2.5	ok	even [M+H] ⁺


¹H-NMR (500 MHz) for compound 2-(2-tolylamino)-2-oxoethyl-5-aminolevulinic (1k)



¹³C-NMR (125,7 MHz) for compound **1k**



ESI MS/MS spectrum of m/z ([M+H]⁺ cation of compound **1k** (collision Energy 10 eV)



Meas. m/z	Formula	m/z	err [ppm]	e ⁻ Conf N-Rule	mSigma
108.08049	C 7 H 10 N	108.08078	2.6	even	ok
114.05471	C 5 H 8 N O 2	114.05495	2.1	even	ok
148.07567	C 9 H 10 N O	148.07569	0.2	even	ok
154.04918	C 7 H 8 N O 3	154.04987	4.5	even	ok
166.08551	C 9 H 12 N O 2	166.08626	4.5	even	ok
261.12335	C 14 H 17 N 2 O 3	261.12337	0.1	even	ok
279.13334	C 14 H 19 N 2 O 4	279.13393	2.1	even	ok